Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | USP19 | O94966 | 13/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14406952 | 0.77 | BRD4 (0.38) | KDM4EALDH1A1POLBMAPTUSP19 | |
| SCHEMBL11983452 | 0.71 | ALDH1A1 (0.60) | KDM4EALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL18102201 | 0.71 | ALDH1A1 (0.60) | KDM4EALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL11929541 | 0.71 | ALDH1A1 (0.59) | KDM4EALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL24989822 | 0.70 | KDM4E (0.58) | KDM4EALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL27739339 | 0.70 | KDM4E (0.58) | KDM4EALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL4591133 | 0.69 | KDM4E (1.00) | KDM4EALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL14407047 | 0.68 | ALDH1A1 (0.56) | KDM4EALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL16075165 | 0.68 | KDM4E (0.51) | KDM4EALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL11929544 | 0.68 | KDM4E (0.56) | KDM4EALDH1A1POLBMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | KDM4E 2769/4885ALDH1A1 4469/4885POLB 4377/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | KDM4E 2769/4885ALDH1A1 4469/4885POLB 4377/4885 |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | KDM4E 3641/4885ALDH1A1 4051/4885POLB 4413/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | KDM4E 3641/4885ALDH1A1 4051/4885POLB 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.